Despite the safety concerns plaguing Abbott‘s (NYSE:ABT) Absorb device, companies developing bioresorbable scaffolds are not discouraged. This week at the annual Transcatheter Cardiovascular Therapeutics Conference in Denver, a number of companies touted the safety data coming from clinical trials of their products. Among them were Reva Medical (ASX:RVA) and Biotronik – here’s an overview of that data. Get the full story at […]
One Drop partners with Fitbit to bring diabetes data to people’s wrists
One Drop announced yesterday that it landed a multi-part collaboration with Fitbit (NYSE:FIT). The group’s first initiative will be to integrate Fitbit’s data onto One Drop’s mobile app for diabetes management, the company said, in the hopes to helping users better understand how physical activity impacts blood glucose management. Get the full story at our sister site, Drug […]
Senseonics tops sales estimates with Q3 results
Shares in Senseonics (NYSE:SENS) fell today even though the medical technology company beat expectations on Wall Street with its third quarter results. The Germantown, Md.-based company posted a loss of -$17.4 million on sales of $2.1 million for the 3 months ended Sept. 30. Get the full story at our sister site, Drug Delivery Business News.
Long-term data for Abbott’s Absorb “highlight the need for continued improvements” in BRS tech
Hours before Abbott (NYSE:ABT) presented three-year data from a pivotal trial of its Absorb bioresorbable scaffold, the FDA updated a letter to healthcare providers, writing that the device continues to show an increased rate of major adverse cardiac events and thrombosis compared to patients treated with a drug-eluting stent. “The FDA’s recommendations for health care providers outlined […]
Novo Nordisk shares slip on cautious guidance, insulin pricing concerns
Shares in Novo Nordisk (NYSE:NVO) fell slightly today after the insulin-maker met expectations on Wall Street with its third quarter results, but issued cautious sales guidance for 2018. The company’s chief executive expressed concerns that draft legislation to make drug pricing more transparent could potentially hurt the industry, according to Reuters. Get the full story at our sister […]
Study: Glooko’s mobile app boosts glycemic control in patients with Type II diabetes
Glooko touted data today from a feasibility study evaluating the impact of its mobile insulin dosing system for people with Type II diabetes who are taking long-acting insulin. The Mountain View, Calif.-based company said it hoped to better understand the extent to which its system can make appropriate insulin titration adjustments and improve a patient’s glycemic […]
Pfizer posts Street-beating Q3, raises full-year earnings forecast
Shares in Pfizer (NYSE:PFE) fell slightly today even though the pharmaceutical giant beat expectations on Wall Street with its third quarter results. The New York-based company posted profits of $2.84 billion, or 47¢ per share, on sales of $13.17 billion, for sales growth of 1% compared with last year’s third quarter results. Get the full story at […]
Agile Therapeutics touts late-stage trial for once-weekly contraceptive patch
Agile Therapeutics (NSDQ:AGRX) touted data today from a Phase III trial of its once-weekly, low-dose hormonal contraceptive patch, Twirla. The study showed that women experienced mean decreases in length of bleeding and spotting episodes, the Princeton, N.J.-based company reported. Get the full story at our sister site, Drug Delivery Business News.
TCT 2017: OrbusNeich’s dual therapy stent non-inferior to Abbott’s Xience DES in 1-year follow-up
OrbusNeich touted results today from a pivotal registration study comparing its Combo dual therapy stent with Abbott’s (NYSE:ABT) Xience stent in patients with ischemic heart disease. The trial is designed to evaluate the effectiveness of OrbusNeich’s combined endothelial progenitor cell capture and drug-eluting stent. The data showed that the device is non-inferior to Abbott’s drug-eluting stent after […]
Elixir Medical unveils ‘bioadaptive’ metallic drug-eluting stent at TCT 2017
Interventional cardiologists have used stents to keep the heart’s coronary arteries open for decades. Transitioning from bare-metal stents to drug-eluting stents in the early 2000s brought tremendous benefits for patients. “But over the last 10 years, the technological progress and meaningful clinical improvements have plateaued,” Elixir Medical CEO Motasim Sirhan told Drug Delivery Business News. “When you stent an artery today, you […]
Philips highlights wearable tech in healthcare with pitch competition
Entrepreneurs joined Royal Philips (NYSE:PHG) executives and other players in the medical device industry last week at Philips’ Wearables & Chronic Care Challenge to tout their novel wearable technology and compete for a chance to win $10,000. It was the second time that Philips has hosted the event, in-line with the two-year anniversary of the company’s […]